PULMONARY PERFUSION IN LONG-TERM SURVIVORS OF COVID-19 RELATED SEVERE ARDS TREATED BY EXTRACORPOREAL MEMBRANE OXYGENATION | Czech Cardiovascular Research and Innovation Days 2023

Pulmonary perfusion in long-term survivors of COVID-19 related severe ARDS treated by extracorporeal membrane oxygenation

Introduction. COVID-19 is considered to be a hypercoagulant state with an increased risk of developing venous thromboembolic events (VTE). Whether severe COVID-19 infection requiring ECMO support leads to chronic pulmonary perfusion abnormalities and chronic thromboembolic pulmonary disease/hypertension remains unclear.
Purpose. To evaluate chronic pulmonary perfusion abnormalities in long-term survivors of COVID-19 related severe ARDS treated by ECMO. The incidence of VTE during the acute phase was assessed.
Methods. At least 3 months after ECMO explantation, pulmonary perfusion was examined by V/Q SPECT or V/Q planar scintigraphy.
Results. There were 172 COVID-19 patients treated by ECMO at General University Hospital in Prague between March 2020 and November 2021 and only 80 of them were successfully explanted. We enrolled 37 patients after ECMO explantation (27 % female, mean age 52 years). The median duration of ECMO support was 12 days. In 24 (65 %) patients in the acute phase, VTE was recorded (23 patients developed ECMO cannula-related DVT, 5 of them also had a pulmonary embolism and 1 central catheter-associated DVT). Acute pulmonary embolism was verified by CT angiography in 2 patients before ECMO implantation, in 2 patients during ECMO, and in 1 after ECMO explantation. The median duration between ECMO explantation and assessment of pulmonary perfusion was 420 days. No segmental or larger mismatched perfusion defects have been detected in any of the patients.
Conclusion. In long-term survivors of COVID-19 related severe ARDS treated by ECMO, despite frequent acute VTE, no sequelae suggesting chronic pulmonary perfusion abnormalities were detected.

PULMONARY PERFUSION IN LONG-TERM SURVIVORS OF COVID-19 RELATED SEVERE ARDS TREATED BY EXTRACORPOREAL MEMBRANE OXYGENATION Topic: Pulmonary hypertension
Type: Presentation - doctors , Number in the programme: 47


Miksová L.¹, Dytrych V.², Ptáčník V.³, Balík M.⁴, Linhart A.⁵, Bělohlávek J.⁵, Jansa P.⁵ ¹ II. interní klinika kardiologie a angiologie, Všeobecná fakultní nemocnice v Praze, Prague, ² 2nd Department of Medicine - Clinical Department of Cardiology and Angiology, General University Hospital in Prague, Prague, ³ Institute of Nuclear Medicine of the 1st Faculty of Medicine and General University Hospital in Prague, General University Hospital in Prague, Prague, ⁴ Department of Anesthesiology and Intensive Care of the 1st Faculty of Medicine and General University Hospital in Prague, General University Hospital in Prague, Prague, ⁵ Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine, General University Hospital in Prague, Prague
Pulmonary perfusion in long-term survivors of COVID-19 related severe ARDS treated by extracorporeal membrane oxygenation Introduction. COVID-19 is considered to be a hypercoagulant state with an increased risk of developing venous thromboembolic events (VTE). Whether severe COVID-19 infection requiring ECMO support leads to chronic pulmonary perfusion abnormalities and chronic thromboembolic pulmonary disease/hypertension remains unclear. Purpose. To evaluate chronic pulmonary perfusion abnormalities in long-term survivors of COVID-19 related severe ARDS treated by ECMO. The incidence of VTE during the acute phase was assessed. Methods. At least 3 months after ECMO explantation, pulmonary perfusion was examined by V/Q SPECT or V/Q planar scintigraphy. Results. There were 172 COVID-19 patients treated by ECMO at General University Hospital in Prague between March 2020 and November 2021 and only 80 of them were successfully explanted. We enrolled 37 patients after ECMO explantation (27 % female, mean age 52 years). The median duration of ECMO support was 12 days. In 24 (65 %) patients in the acute phase, VTE was recorded (23 patients developed ECMO cannula-related DVT, 5 of them also had a pulmonary embolism and 1 central catheter-associated DVT). Acute pulmonary embolism was verified by CT angiography in 2 patients before ECMO implantation, in 2 patients during ECMO, and in 1 after ECMO explantation. The median duration between ECMO explantation and assessment of pulmonary perfusion was 420 days. No segmental or larger mismatched perfusion defects have been detected in any of the patients. Conclusion. In long-term survivors of COVID-19 related severe ARDS treated by ECMO, despite frequent acute VTE, no sequelae suggesting chronic pulmonary perfusion abnormalities were detected.

VIEW AN ABSTRACT